XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Liquidity and Capital Resources (Details) (USD $)
6 Months Ended
Jun. 30, 2012
Dec. 31, 2011
Jun. 30, 2011
Dec. 31, 2010
Estimated projected expenditure [Line Items]        
Cash and cash equivalents $ 11,859,009 $ 17,988,590 $ 7,023,176 $ 6,324,430
Marketable securities 15,067,770 18,057,672    
Currently projected expenditures for clinical programs 23,800,000      
Aldoxorubicin [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 9,300,000      
Bafetinib [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 300,000      
Tamibarotene [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 5,500,000      
General Operation [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 2,400,000      
Other General and Administrative Expenses [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs $ 6,300,000